Bridge RNA & Gene Writing Patents

Bridge RNA and gene writing patents cover programmable-recombinase innovations; bridge-RNA and guide innovations; mobile-genetic-element (retroelement) innovations; and large-DNA-insertion innovations — with IP held by the institutions and companies pioneering 'gene writing' (the next genome-editing frontier: precisely inserting WHOLE genes, not just editing single letters). WHAT IS GENE WRITING / BRIDGE RNA: base and prime editing make small DNA changes (single letters, small indels); GENE WRITING aims to programmably INSERT, invert, or delete LARGE pieces of DNA (whole genes/cassettes) at a chosen genomic site without double-strand breaks — enabling, e.g., replacing an entire mutated gene. MAJOR HOLDERS: ARC INSTITUTE (Patrick Hsu / Silvana Konermann): BRIDGE RECOMBINASES — an enzyme from the IS110/IS621 family of 'insertion sequences' guided by a 'BRIDGE RNA' (a non-coding RNA with two loops — one that base-pairs with the genomic TARGET and one that base-pairs with the DONOR DNA) — making RNA-PROGRAMMABLE DNA recombination that can insert, excise, or invert sequences (a landmark 2024 discovery); the bridge-RNA/recombinase system is foundational gene-writing IP. TESSERA THERAPEUTICS: the Gene Writing platform — engineered MOBILE GENETIC ELEMENTS (retrotransposons / R2-LINE retroelements) that use an RNA template reverse-transcribed and written directly into the genome (RNA Gene Writers), for both small edits and large insertions. OTHERS: Prime Medicine (twinPE/PASTE — prime editing + serine integrase landing sites for large insertion), serine-integrase (Bxb1) approaches, and academic recombinase/integrase holders. Bridge recombinases, retroelement Gene Writers, and integrase-based insertion are the core gene-writing patent domains — and this is a very young, fast-moving field with foundational IP still being staked.

Bridge-recombinase enzyme innovations; bridge-RNA design innovations; reprogramming and targeting innovations; and insertion/inversion/deletion innovations represent core bridge-RNA gene-writing patent domains — and the RNA-programmable recombinase plus its bridge RNA are the foundational, novel invention. BRIDGE-RECOMBINASE PATENTS: the recombinase enzyme (from IS110/IS621 and related insertion-sequence families) that catalyzes RNA-guided DNA recombination, enzyme variants, and engineering for efficiency/specificity in human cells (the natural systems are bacterial — adapting them to mammalian genome editing is key). BRIDGE-RNA PATENTS: the bridge RNA design — the dual-loop non-coding RNA whose 'target loop' programs which genomic site to act on and whose 'donor loop' programs which DNA to insert (independently reprogrammable target AND donor specificity — a distinctive advantage over CRISPR, which only programs the target) — including loop sequences, stabilization, and the reprogramming rules. TARGETING / REPROGRAMMING PATENTS: methods to reprogram the system to any target and donor, specificity/off-target reduction, and PAM-like requirements. INSERTION / RECOMBINATION PATENTS: programmable insertion (writing in a gene), excision (deleting a region), and inversion (flipping a sequence) — large-cargo recombination WITHOUT double-strand breaks (avoiding the indels/translocations of nuclease editing) and WITHOUT a donor-DNA template needing homology. The bridge recombinase, the dual-loop bridge RNA (independently programmable target + donor), and large-DNA insertion/inversion without double-strand breaks are the highest-value, most-foundational gene-writing IP.

Mobile-genetic-element and retroelement innovations; RNA-template Gene-Writer innovations; serine-integrase and landing-site innovations; and delivery and specificity innovations represent additional gene-writing patent domains — and the different gene-writing modalities each have distinct, valuable IP. RETROELEMENT GENE-WRITER PATENTS: engineered mobile genetic elements (non-LTR retrotransposons / R2 and LINE-derived retroelements — Tessera) that carry their own RNA template and a reverse transcriptase, writing the template sequence directly into a target genomic site (RNA Gene Writing) — the engineered element, the RNA template design, target retargeting, and the all-RNA-deliverable format (a delivery advantage). SERINE-INTEGRASE / LANDING-SITE PATENTS: large-serine integrases (Bxb1-type) that integrate a donor at a pre-installed 'landing site' — combined with prime editing to first install the landing site and then integrate a large cargo (twinPE/PASTE — Prime Medicine), and directed-evolution of integrases for new specificities; this two-step approach enables very large insertions. DELIVERY PATENTS: delivering the writer system — all-RNA/mRNA + LNP (transient, no DNA, a safety/delivery advantage), AAV (size-constrained), and virus-like particles; the compactness and all-RNA-deliverability of bridge/retroelement systems versus larger CRISPR-integrase combos is a delivery differentiator. SPECIFICITY / SAFETY PATENTS: off-target insertion reduction, and the absence of double-strand breaks (a safety advantage). Retroelement Gene Writers (all-RNA), integrase landing-site systems for very large cargo, and compact deliverable writers are high-value gene-writing IP — and delivery/compactness is a key competitive axis.

Gene writing startup IP strategy must navigate Arc Institute bridge-recombinase/bridge-RNA foundational patents (very new, 2024 — foundational IP being staked now), Tessera Gene-Writing retroelement patents, Prime Medicine twinPE/PASTE and prime-editing IP, serine-integrase prior art, the underlying CRISPR/recombinase and reverse-transcriptase estates, the early-stage nature of the field (efficiency and delivery in human cells are unproven hurdles), and a §101-light landscape (concrete molecular systems); understand that this is a FOUNDATIONAL land-grab moment (the core systems — bridge recombinases, retroelement writers, integrase landing sites — are being patented now), that the durable IP is in the specific writer system (enzyme + guide/template), reprogramming, large-cargo insertion, and delivery, and that demonstrating efficiency/specificity in human cells is the gating challenge; identify whitespace in engineered bridge systems, retroelement writers, delivery, and large-cargo insertion. GENE-WRITING STARTUP IP STRATEGY: THIS IS A FOUNDATIONAL LAND-GRAB — STAKE THE WRITER SYSTEM NOW: bridge recombinases (Arc) and retroelement Gene Writers (Tessera) are very new — the foundational enzyme + guide/template systems are being patented now, so file early on your specific writer (enzyme variant + bridge RNA / RNA template), reprogramming, and large-cargo insertion; PROGRAMMABLE LARGE-DNA INSERTION IS THE HIGHEST-VALUE FRONTIER: inserting WHOLE genes precisely (vs base/prime editing's small edits) without double-strand breaks is the prize — bridge RNA's independently-programmable target AND donor is a distinctive, defensible advantage; HUMAN-CELL EFFICIENCY AND SPECIFICITY ARE THE GATING (AND PATENTABLE) CHALLENGE: the natural systems are bacterial/low-efficiency — engineering them to work efficiently and specifically in human cells is both the make-or-break hurdle and high-value IP; DELIVERY AND COMPACTNESS ARE A COMPETITIVE AXIS: all-RNA-deliverable, compact writers (LNP, transient, no DSB) have a real delivery/safety advantage — patent the deliverable format; CLEAR UNDERLYING CRISPR/RT/INTEGRASE FTO: your system may use a reverse transcriptase, a Cas component, or an integrase — map that FTO; INTEGRASE LANDING-SITE SYSTEMS ENABLE VERY LARGE CARGO: twinPE/PASTE-style two-step integration (Prime Medicine) is an alternative large-insertion route; WHEN TO PATENT: NOVEL WRITER WITH MEASURED PERFORMANCE: file once a system shows measured results (insertion/recombination efficiency in human cells + cargo size + specificity/off-target + delivery + no-double-strand-break) vs. existing editing/integration — measured insertion efficiency, cargo size, specificity, and deliverability are the critical gene-writing IP metrics; KEY FTO CHECKLIST: Arc Institute bridge recombinase IS110/IS621 + dual-loop bridge RNA (independently programmable target + donor) RNA-guided recombination insert/excise/invert; Tessera Gene Writing R2/LINE retroelement RNA-template reverse-transcribe into genome all-RNA; Prime Medicine twinPE/PASTE prime-editing + serine integrase landing site large insertion; Bxb1/serine integrase directed evolution; human-cell efficiency/specificity engineering; no-double-strand-break large-cargo insertion; all-RNA/LNP/VLP delivery compactness; underlying CRISPR/reverse-transcriptase/integrase FTO.